NANCY REHFELD: Open Payments
NPI 1093198848 · GLENDORA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,718 in 87 payments from 11 companies in 2025. Trend: 2023 $1,158 · 2024 $1,233 · 2025 $1,718
Food & beverage: $1,718
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 11 | $317 |
| ABBVIE INC. | 17 | $283 |
| Otsuka America Pharmaceutical, Inc. | 18 | $275 |
| Axsome Therapeutics, Inc. | 11 | $248 |
| E.R. Squibb & Sons, L.L.C. | 5 | $176 |
| Teva Pharmaceuticals USA, Inc. | 14 | $167 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $107 |
| Janssen Pharmaceuticals, Inc | 3 | $62 |
| Tris Pharma Inc | 2 | $35 |
| Neurocrine BioSciences, Inc. | 1 | $24 |
Products named: ARISTADA, VRAYLAR, Auvelity, COBENFY, REXULTI, CAPLYTA, ABILIFY ASIMTUFII, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
